Spero Therapeutics (NASDAQ:SPRO) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Spero Therapeutics (NASDAQ:SPRO) in a report released on Thursday,Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock.

Several other equities research analysts have also recently weighed in on the stock. Evercore ISI cut shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective for the company. in a research report on Friday, December 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a report on Friday, November 15th. Finally, TD Cowen reissued a “hold” rating on shares of Spero Therapeutics in a research note on Monday, November 18th.

Spero Therapeutics Stock Performance

NASDAQ:SPRO opened at $0.87 on Thursday. Spero Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $1.89. The company has a 50 day simple moving average of $1.02 and a two-hundred day simple moving average of $1.21. The company has a market capitalization of $47.43 million, a PE ratio of 12.43 and a beta of 0.63.

Hedge Funds Weigh In On Spero Therapeutics

An institutional investor recently raised its position in Spero Therapeutics stock. Renaissance Technologies LLC boosted its holdings in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 14.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 975,952 shares of the company’s stock after purchasing an additional 121,492 shares during the quarter. Renaissance Technologies LLC owned about 1.81% of Spero Therapeutics worth $1,269,000 at the end of the most recent quarter. Institutional investors and hedge funds own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.